MedTrace Logo

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-08-17

Study results available
· View outcomes & findings →

Summary

The study is designed to investigate the relationship between insulin resistance and non-alcoholic fatty liver disease (NAFLD) and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining associations between hepatic and peripheral insulin sensitivity, hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, beta-cell function and body fat distribution.

Conditions

Interventions

DRUG

fenofibrate

micronized fenofibrate 200 mg 1 po qd

DRUG

pioglitazone

pioglitazone 30 mg po qd

DRUG

placebo

placebo 1 capsule po qd

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Kristina M Utzschneider, MD · VA Puget Sound Health Care System, Seattle

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2013-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289639 on ClinicalTrials.gov